Cross Stefan 4
4 · HedgePath Pharmaceuticals, Inc. · Filed Feb 12, 2018
Insider Transaction Report
Form 4
Cross Stefan
Director
Transactions
- Purchase
Common Stock
2017-12-19$162660.00/sh−600,000$97,596,000,000→ 0 total
Footnotes (1)
- [F1]On December 19, 2017, Stefan Cross sold 600,000 shares of Common Stock to Mayne Pharma Ventures Pty Ltd.